While melanoma incidence is lower in individuals with darker skin tones, persistent disparities exist in mortality rates, particularly among African American/Black and Hispanic patients. The many factors for higher mortality rates in racial and ethnic minority populations include low public awareness of at-risk populations and a lower index of concern by dermatologists and other clinicians. Additionally, melanoma types that are more common in skin of color are deemed “rare” and typically occur in areas of the body not exposed to UV radiation. Hence, melanoma lesions are more likely to appear in places less frequently surveyed, leading to later diagnoses and worse prognosis. This has led to an education gap in clinicians, particularly in diagnosing and screening practices.
This live CMEO Briefcase will focus on three patients from racial and ethnic minority populations with melanoma and outline best practices for screening to reduce disparities and improve melanoma morbidity and mortality rates in patients of color.
At the end of this CME/CE activity, participants should be able to implement best practices to improve melanoma morbidity and mortality rates in patients of color.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Peek has no disclosures to report.
Dr. Alexis reports that he receives grants from Almirall; Amgen Inc; Arcutis Biotherapeutics; Bristol Myers Squibb; Cara Therapeutics; Dermavant Sciences, Inc.; Galderma; Leo Pharma; Menlo Therapeutics Inc.; Novartis; and Valeant (Bausch Health). He is a consultant for Abbvie Inc.; AllerGen; Almirall; Amgen Inc.; Arcutis Biotherapeutics; Bausch Health; Beiersdorf; Bristol Myers Squibb; Dermavant Sciences, Inc.; Galderma; Janssen; Leo Pharma; L’Oreal; Pfizer Inc.; Sanofi-Regeneron; Sol-Gel Technologies Ltd; UCB; Valeant (Bausch Health); VisualDx; and Vyne Therapeutics. He is on the speakers bureau for Pfizer, Inc; Regeneron; and SANOFI-Genzyme.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-199-H01-P.
Call us at 877.CME.PROS (877.263.7767).